Cancer epitranscriptomics is a new field of research that investigates chemical modifications on RNA molecules and their involvement in tumor growth, progression, and response to therapy. The session "Cancer Epitranscriptomics" aims at elucidating how RNA modifications like m6A methylation affect gene expression, cellular signaling, and cancer biology.".
These epitranscriptomic marks can control important processes such as cell proliferation, apoptosis, metastasis, and evasion from the immune response. Aberrant regulation of epitranscriptomic marks is generally linked with aggressive tumor behavior and resistance to therapy. Elucidation of these mechanisms gives rise to new diagnostic, prognostic, and therapeutic strategies.
The session discusses advanced methods for the detection and analysis of RNA modifications, such as high-throughput sequencing and bioinformatic tools. Epitranscriptomic insights are being applied to the development of new therapeutic interventions, such as to target RNA-modifying enzymes or employ RNA-based therapeutics to regulate gene expression.
The participants will learn about the principles, research progress, and therapeutic potential of cancer epitranscriptomics. This session highlights the revolutionary potential of RNA modifications in precision oncology, with new approaches to biomarker identification, customized therapy, and the creation of novel cancer drugs.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
